Confronting Inequities in Immuno-Oncology Care

Register now for this dynamic, CPE-certified live webinar at the 2022 AMCP Health Disparities Summit. Our expert pharmacist panel will discuss strategies for providing inclusive, equitable care for all patients with cancer receiving immune checkpoint inhibitor therapy, including the latest evidence on managing immune-related adverse events. Sign up today!


  • Welcome and Opening Remarks
  • Inequities in the Era of Immune-Based Cancer Treatment
  • Immune Checkpoint Inhibition Overview and Recognizing/Tailoring Management of irAEs in Patient Groups Affected by Inequalities/Poor Healthcare Access
  • Quality Improvement Checks and Addressing the Need for Patient Support to Achieve Equitable Care
  • Question and Answer Session


Date / Time
Event Details


Jessica Davis, PharmD

Clinical Pharmacist Coordinator
Department of Adult Hematology/Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Kamakshi V. Rao, PharmD, BCOP, FASHP

Assistant Director
Department of Pharmacy
University of North Carolina Medical Center
Adjunct Professor of Clinical Education
Division of Practice Advancement and Clinical Education
UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina

Program Overview
This program is a 1-hour, ACPE-accredited, live virtual satellite symposium at the 2022 Academy of Managed Care Pharmacy (AMCP) Health Disparities Summit that is designed to educate HCPs on the latest evidence-based cancer immunotherapy treatment and immune-related AE (irAE) management and to increase awareness of and provide educational resources and training to recognize and address cancer health disparities based on specific drivers of inequity, including racial, socioeconomic, sex, gender identity, and geography.

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in providing inclusive and equitable care for all patients with cancer, including those patients eligible for or receiving immunotherapy.

Target Audience
The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with cancer as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patient populations and social determinants of health that increase risk for poor prognosis secondary to health disparities
  • Discuss management of immune-related adverse events in patient groups affected by inequalities and poor healthcare access
  • Incorporate health disparity mitigation strategies into the care of all patients receiving immune checkpoint inhibitor therapy and experiencing immune-related adverse events
  • Describe education, quality improvement, and other support strategies to ensure patients with cancer receive optimal and equitable care


CE Accreditation


ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-187-L01-P has been assigned to this live application-based activity (initial release date 6/9/2022). This activity is approved for 1.0 contact hours (0.1 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.